Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.

James Larkin(Trinity College Dublin), Antoni Ribas(University of California, Los Angeles), Claus Garbe(University Children's Hospital Tübingen), Brigitte Dréno(Inserm), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Michele Maio(University of Siena), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grant A. McArthur(The University of Melbourne), Ilsung Chang, Stephen P. Hack, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Daniil Stroyakovskiy(Shikoku Cancer Center), L. Thomas, Victoria Atkinson(Greenslopes Private Hospital), Isabelle Rooney, Yibing Yan, Matthew Wongchenko

Journal of Clinical Oncology

May 20, 2015

Cited by 48

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|Journal of Clinical Investigation|2017|3.9k

|New England Journal of Medicine|2019|3.7k

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced <i>BRAF</i>-mutated melanoma.